Rhythm Pharmaceuticals Stock Alpha and Beta Analysis
| RYTM Stock | USD 59.92 0.02 0.03% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rhythm Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rhythm Pharmaceuticals over a specified time horizon. Remember, high Rhythm Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rhythm Pharmaceuticals' market risk premium analysis include:
Beta 2.06 | Alpha 0.26 | Risk 3.22 | Sharpe Ratio 0.14 | Expected Return 0.46 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rhythm |
Rhythm Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rhythm Pharmaceuticals market risk premium is the additional return an investor will receive from holding Rhythm Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rhythm Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rhythm Pharmaceuticals' performance over market.| α | 0.26 | β | 2.06 |
Rhythm Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rhythm Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Rhythm Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rhythm Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Rhythm Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rhythm Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rhythm Pharmaceuticals stock market price indicators, traders can identify Rhythm Pharmaceuticals position entry and exit signals to maximize returns.
Rhythm Pharmaceuticals Return and Market Media
The median price of Rhythm Pharmaceuticals for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 50.24 with a coefficient of variation of 10.08. The daily time series for the period is distributed with a sample standard deviation of 5.24, arithmetic mean of 52.02, and mean deviation of 4.01. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 18300 shares by Good Jennifer L of Rhythm Pharmaceuticals at 4.15 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 7501 shares by Tetrault Lynn A. of Rhythm Pharmaceuticals at 18.99 subject to Rule 16b-3 | 09/10/2024 |
3 | Disposition of 3199 shares by Tetrault Lynn A. of Rhythm Pharmaceuticals at 50.0369 subject to Rule 16b-3 | 09/11/2024 |
4 | Disposition of 3200 shares by Pamela Cramer of Rhythm Pharmaceuticals at 50.0056 subject to Rule 16b-3 | 09/20/2024 |
5 | Acquisition by Yann Mazabraud of 8905 shares of Rhythm Pharmaceuticals subject to Rule 16b-3 | 09/27/2024 |
6 | Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 | 10/23/2024 |
7 | Earnings call Rhythm Pharmaceuticals has reported a successful third quarter in 2024 | 11/06/2024 |
8 | Rhythm Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ... | 11/07/2024 |
9 | Disposition of 5312 shares by Joseph Shulman of Rhythm Pharmaceuticals at 21.38 subject to Rule 16b-3 | 11/11/2024 |
10 | PRIMECAP Management Adjusts Stake in Rhythm Pharmaceuticals | 11/13/2024 |
11 | Rhythm Pharmaceuticals EVP sells 4.43m in stock | 11/14/2024 |
12 | RA Capital Management, L.P. Increases Stake in Vaxcyte Inc | 11/15/2024 |
13 | Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic O... | 11/18/2024 |
About Rhythm Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rhythm or other stocks. Alpha measures the amount that position in Rhythm Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.44 | 1.9 | 2.0 | Days Of Inventory On Hand | 499.16 | 338.4 | 241.38 |
Rhythm Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Rhythm Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rhythm Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rhythm Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rhythm Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Rhythm Pharmaceuticals' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rhythm Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Rhythm Pharmaceuticals Backtesting, Rhythm Pharmaceuticals Valuation, Rhythm Pharmaceuticals Correlation, Rhythm Pharmaceuticals Hype Analysis, Rhythm Pharmaceuticals Volatility, Rhythm Pharmaceuticals History and analyze Rhythm Pharmaceuticals Performance. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Rhythm Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.